|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-10-27
|
|
pubmed:abstractText |
To undertake a quantitative benefit-risk analysis of rofecoxib relative to naproxen using an incremental net-benefit (INB) analysis from the societal perspective, using the same data evaluated by the Health Canada and US FDA expert advisory panels.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1099-1557
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 John Wiley & Sons, Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1172-80
|
|
pubmed:dateRevised |
2011-2-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20602338-Computer Simulation,
pubmed-meshheading:20602338-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:20602338-Cyclooxygenase Inhibitors,
pubmed-meshheading:20602338-Humans,
pubmed-meshheading:20602338-Lactones,
pubmed-meshheading:20602338-Models, Biological,
pubmed-meshheading:20602338-Monte Carlo Method,
pubmed-meshheading:20602338-Naproxen,
pubmed-meshheading:20602338-Quality-Adjusted Life Years,
pubmed-meshheading:20602338-Sulfones
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
|
|
pubmed:affiliation |
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. larry.lynd@ubc.ca
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
